News
ICLR
218.22
-0.51%
-1.12
Icon’s Strategic Measures and Partnerships Justify Buy Rating Amid Margin Challenges
TipRanks · 2d ago
ICLR Factor-Based Stock Analysis - Martin Zweig
NASDAQ · 4d ago
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
Barchart · 4d ago
ICON plc draws bullish views at RBC on attractive valuation
Seeking Alpha · 5d ago
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 5d ago
Icon Price Target Announced at $263.00/Share by RBC Capital
Dow Jones · 5d ago
Icon Initiated at Outperform by RBC Capital
Dow Jones · 5d ago
RBC Capital Initiates Coverage On Icon with Outperform Rating, Announces Price Target of $263
Benzinga · 5d ago
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 5d ago
Icon Is Maintained at Buy by Citigroup
Dow Jones · 6d ago
Icon Price Target Cut to $290.00/Share From $300.00 by Citigroup
Dow Jones · 6d ago
Icon initiated with an Outperform at RBC Capital
TipRanks · 6d ago
Citigroup Maintains Buy on Icon, Lowers Price Target to $290
Benzinga · 6d ago
Icon price target lowered to $290 from $300 at Citi
TipRanks · 6d ago
Weekly Report: what happened at ICLR last week (1230-0103)?
Weekly Report · 6d ago
Weekly Report: what happened at ICLR last week (1223-1227)?
Weekly Report · 12/30/2024 09:18
Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 45% Discount?
Simply Wall St · 12/28/2024 14:16
Fortrea: Turning Around As The Activists Move In
Seeking Alpha · 12/26/2024 09:30
Weekly Report: what happened at ICLR last week (1216-1220)?
Weekly Report · 12/23/2024 09:19
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
Barchart · 12/23/2024 06:15
More
Webull provides a variety of real-time ICLR stock news. You can receive the latest news about ICON PLC through multiple platforms. This information may help you make smarter investment decisions.
About ICLR
More
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.